# Intersect ENT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intersect-ent

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.intersectent.com
- Total disclosed funding: $82M
- Latest round: Series D (Feb 15, 2013)
- Investors on record: 6

## About

Intersect ENT Inc., based in the US, specializes in innovative medical technology focused on ear, nose, and throat (ENT) disorders, particularly chronic sinusitis treatments through advanced sinus implant solutions.Intersect ENT Inc. is a medical technology firm dedicated to addressing ENT-related health issues. Founded in 2003 and headquartered in Menlo Park, California, the company has undergone significant growth since its inception. In June 2015, it raised USD 89.55 mn in a Private Placement/Follow on funding round, bringing its total amount raised to USD 89.55 mn. The company has completed 11 deals in total, with the most recent deal occurring on June 2, 2015. The firm’s founder and CEO is not mentioned in available data.Intersect ENT Inc. offers the PROPEL™ sinus implant, a device designed for surgical patients aged 18 and older. This implant helps maintain sinus patency while delivering mometasone furoate, a corticosteroid, directly to the sinus mucosa post-surgery. The PROPEL™ product line includes the PROPEL™, PROPEL™ Mini, and PROPEL™ Contour, each tailored for different sinus anatomies. Its products primarily serve healthcare providers, including ENT specialists and surgical centers across North America, Europe, and parts of Asia-Pacific.In 2021, Intersect ENT Inc. reported a revenue of USD 106.75 mn alongside an EBITDA of USD -134.62 mn.The company plans to leverage its recent funding of USD 89.55 mn for business expansion and market approach initiatives. Intersect ENT Inc. aims to introduce new products targeting chronic sinusitis within the next 12 months while pursuing entry into additional geographic markets across Europe and Asia by 2024. This strategic growth will enhance its presence in the medical technology sector.

## Funding rounds

- Series D, Feb 15, 2013, $21M — Kleiner Perkins, US Venture Partners, Norwest Venture Partners, PTV Healthcare Capital, Medtronic plc
- Series C, Sep 1, 2011, $16M — Kleiner Perkins, US Venture Partners, PTV Healthcare Capital, Medtronic plc
- Series C, Nov 1, 2010, $16M — Kleiner Perkins, US Venture Partners, PTV Healthcare Capital, Medtronic plc
- Series B, Jun 6, 2008, $20M — Kleiner Perkins, US Venture Partners, PTV Healthcare Capital
- Series A, Sep 18, 2007, $3.5M — Kleiner Perkins, US Venture Partners
- Series A, Apr 18, 2006, $6.2M — Kleiner Perkins, US Venture Partners, Montreux Equity Partners

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C, Series D
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B, Series C, Series D
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series A
- PTV Healthcare Capital (https://capitalatlas.ai/funds/ptv-healthcare-capital) — Series B, Series C, Series D
- Medtronic plc — Series C, Series D
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series D